Abstract: Background: Psoriasis has been associated with co-morbidities and elevated cardiovascular risk. oBjectives: To analyze the relationships among metabolic syndrome, cardiovascular risk, C-reactive protein, gender, and Psoriasis severity. Methods: In this cross-sectional study, plaque Psoriasis patients (n=90), distributed equally in gender, were analyzed according to: Psoriasis Area and Severity Index, cardiovascular risk determined by the Framingham risk score and global risk assessment, C-reactive protein and metabolic syndrome criteria (NCEPT-ATP III). results: Metabolic syndrome frequency was 43.3% overall, without significance between genders (P=0.14); but women had higher risk for obesity (OR 2.56, 95%CI 1.02-6.41; P=0.04) and systemic arterial hypertension (OR 3.29, 95%CI 1.39-7.81; P=0.006). The increase in the Psoriasis Area and Severity Index also increased the risk for metabolic syndrome (OR 1.060, 95%CI 1.006-1.117; P=0.03). Absolute 10-year cardiovascular risk was higher in males (P=0.002), but after global risk assessment, 51.1% patients, 52.2% women, were re-classified as high-intermediate cardiovascular risk; without significance between genders (P=0.83). C-reactive protein level was elevated nearly six-fold overall, higher in metabolic syndrome (P=0.05), systemic arterial hypertension (P=0.004), and high-intermediate 10-year cardiovascular risk patients (P<0.001); positively correlated to: Framingham risk score (P<0.001; r=0.60), absolute 10-year cardiovascular risk (P<0.001; r=0.58), and age (P=0.001; r=0.35); but not to Psoriasis Area and Severity Index (P=0.14; r=0.16); increased the 10-year cardiovascular risk (R2=33.6; P<0.001), MetS risk (OR 1.17, 95%CI 0.99-1.37; P=0.05) and with age (P=0.001). HDL-cholesterol level was higher in normal C-reactive protein patients (t=1.98; P=0.05). study liMitations: Restricted sample, hospital-based and representative of a single center and no specification of psoriatic arthritis. conclusions: Psoriasis, metabolic syndrome, systemic arterial hypertension and age share the increase in C-reactive protein, which could implicate in additional burden for increasing the cardiovascular risk and be an alert for effective interventions.
INTRODUCTION
Psoriasis (PsO) is an immune-mediated inflammatory disease that primarily affects skin and joints, with systemic repercussions that raise the risk of developing cardio-and cerebrovascular diseases (CCVD). [1] [2] [3] [4] [5] [6] [7] [8] Among a variety of co-morbidities, obesity, diabetes mellitus (DM), and metabolic syndrome (MetS) have been consistently associated with PsO. [8] [9] [10] [11] [12] [13] [14] tional Cholesterol Education Program -Adult Treatment Panel III (NCEP-ATP III). [15] [16] [17] [18] The mechanistic links between the inflammation of PsO, metabolic alterations and increased risk of CCVD are not fully understood 2, [12] [13] [14] PsO attributable risk remains difficult to assess due to confounding factors. 19 However, large studies indicate that the increased cardiovascular risk (CVR) is at least partially attributable to PsO and independent of the presence of metabolic co-morbidities.
Severe psoriasis has been considered as an independent risk factor for acute heart attack, stroke and cardiovascular mortality when adjusting for major risk factors. 4, 5, 20, 21 C-reactive protein (CRP) is an acute phase protein that can be elevated in both infectious and inflammatory processes. 22 There are strong evidences of relationship between CRP and coronary heart disease (CHD), and also records of elevated CRP levels on MetS. 23, 24 Elevated CRP levels and other inflammatory markers have been associated with skin disease activity of PsO, mainly psoriatic arthritis (PsA) and generalized pustular PsO. [25] [26] [27] [28] [29] This study had the purpose to evaluate the prevalence of
MetS and its components, according to gender and PsO severity, and the relationships among MetS, CRP and CVR in PsO patients.
METHODS

Subjects
We conducted a cross-sectional hospital-based study after its approval by the Ethics Committee of the Hospital of Clinics of School of Medicine of Ribeirão Preto, University of São Paulo, Brazil, for which were sequentially selected 90 adult subjects with plaque PsO in follow-up at Dermatology outpatient clinic. The severity of PsO was determined using the Psoriasis Area and Severity Index (PASI), according to score values 0 to 72: mild PsO was defined as PASI ≤ 10 and moderate to severe PsO defined as PASI > 10.
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Collection of data, blood samples and laboratory assays The collection of anthropometric data (weight, height, waist circumference) and measurement of systemic blood pressure were obtained by physical examination according to standard procedures. The waist circumference (cm) was performed with flexible tape by positioning at half of the distance between the iliac crest and lower costal border. Systemic blood pressure (BP), diastolic and systolic (mmHg), was measured by analogical sphygmomanometer (Tycos, Welch Allyn, Skaneateles Falls, NY, USA) in the right arm, in the sitting position and after five minutes of rest, and at least two measures were performed for the calculation of mean. The collected blood samples were obtained after fasting of at least 12 hours.
The dosage of fasting glucose (mg/dL) was performed using the glucose-oxidase method; cholesterol, high-density lipoprotein (HDL)-cholesterol and triglyceride (mg/dL) by enzyme-dosing colorimetric method and CRP (mg/dL) by immunoturbidimetry method, with reference value less than 0.5 mg/dL.
Criteria of metabolic syndrome and cardiovascular risk
Criteria used for the diagnosis of MetS were those recommended by the NCEP-ATP III, which is defined by the presence of at least three of these components: 1) increased waist circumference (>   102 cm PsO and 10 men (28.57%) had CVR more than or equal to 20% ( Table   2 ). The CRP levels were positively correlated to age (r = 3.12; P = 0.002). However, after global risk assessment, which considered high-risk equivalents and risk-enhancer factors, 46 (51.1%) patients (22 males and 24 females) were re-classified as high-intermediate CVR; then no statistical significance of the 10-year CVR (P = 0.83) was observed in the gender comparison (Table 1) . In severe to moderate and mild PsO patients, the absolute 10-year CVR was 9.7% and 7.5%, respectively, with no statistical significance (P = 0.18) ( In a subsample (n=72), the CRP average was slightly higher among individuals under topical treatments compared to those using systemic therapies, but with no statistical significance (3.15 mg/ dL vs 2.70 mg/dL; P > 0.05); also, absolute 10-year CVR (9.2% vs 9.5%) and MetS frequencies (31.0% vs. 25.6%; P=0.61), respectively, were similar in these groups. 14, [32] [33] [34] Raised levels of CRP, IL-6 and TNF-alpha have been related to conditions such as smoking, depressive symptoms, and psychosocial stress, which unidirectional and bidirectional relationships with inflammation have been established. [35] [36] [37] Additionally, the elevation of these inflammatory markers has also been associated with some age-related chronic diseases making these relationships non-specific. 38 CRP plays a pro-atherogenic and pro-thrombotic role. Elevated CRP concentration or CRP mRNA can be observed in atherosclerotic plaques, adipose tissue, and CRP synthesis seems to be positively related to leptin levels. 39 Raised high sensitivity CRP levels have been consistently associated with CHD and elevated CVR, and related to cerebrovascular disease, MetS and PsO. [23] [24] [25] [26] [27] [28] [29] 40 Ultimately, as in an interlaced circuit, sustained levels of PsO inflammatory mediators would play a role in the precipitation, maintenance and/or reciprocal relationship of injury with the comorbidities, particularly obesity, insulin resistance, MetS and CCVD. 14, 32, 40 Firstly, these comorbidities need to be recognized beyond the skin involvement, because they potentially represent an extra burden for PsO patients and several are modifiable by interventions.
RESULTS
Comorbidity frequencies and risks
0
DISCUSSION
MetS prevalence has been distinguished across gender, race and ethnic subgroups. [15] [16] [17] In the United States, by the NCEP definition, the estimated MetS prevalence ranges between 24 to 28% of adult men and 23% to 34% of adult women; it was highest for Mexican Americans and lowest for Blacks of both sexes. 15, 16 In a systematic review that included ten cross-sectional studies in Brazilian population, the mean for MetS prevalence Brazil was 29.6% (range 14.9%-65.3%). 41 Among them, two cross-sectional population-based Brazilian studies revealed MetS prevalence of 29.8% and 35.9%, 42, 43 by NCEP-ATP III criteria, respectively. MetS was increased from the youngest (26-34 y) to the oldest (55-64 y) group (15.8% and 48.3%, respectively), as well as in women from the higher to the lowest socioeconomic level. 42 MetS seems highly prevalent in Brazil and significantly associated with age, body mass index, and educational level. [41] [42] [43] A previous hospital-based case-control study demonstrated significantly higher frequency of MetS -NCEP-ATP III criteria-in Italian patients with PsO and 40 years or older compared to the controls with other skin disorders (30.1% vs. 20.6%). 44 In a previous study in Brazilian PsO patients, MetS, SAH and DM frequencies were 44.9%, 43.7% and 15.3 %, respectively. 45 In our sample, MetS frequency was almost similar (43.3%), but SAH (50%) and DM (31.1%) frequencies were higher. Therefore, the two latter components were twofold and fivefold higher compared to
Brazilian population, estimated in 21.4% and 6.2%, respectively. 46 In our study, the MetS frequency of 47.8% in patients older than 40 years seems higher. This age group and women showed a strong tendency for MetS. In fact, women showed higher risk for SAH and obesity, and the risk for Mets was related to an increase of the levels of PsO severity and CRP. Besides PsO severity, also MetS, SAH and age showed a close relationship with an increase in CRP value. High-sensitive CRP has been indicated as an additional criterion to the classical risk factors, to further assess risk for CHD and plan its primary prevention. 23, 47 Since risk equivalents (DM, atherosclerotic disease) and risk enhancers (MetS) are significantly prevalent in PsO patients, they must be considered in these patients, as the CVR global assessment, which adds these parameters to CVR established by FRS. Overall, the literature supports the role of CRP as a laboratory indicator of PsO severity and its relationship to PASI, particularly when the patient is not under the effect of any systemic treatments for at least one month and has no signs of joint involvement. 29 Therefore, PsA does not necessarily correspond to the extension and severity of cutaneous involvement and may carry an extra load of inflammation. 29 Even if remission is achieved by effective PsO treatment, after a marked decline, CRP values can fail to turn to the normal range. 29 The remaining inflammation may play a role in disease relapses and an inflammatory biomarker could work as a possible predictor for the length of remission and chance of re-exacerbation in a therapy course. 29, 48 CRP cardio-toxicity and its close relationship to all-cause mortality rate (29) emphasize an approach for the most effective therapies for reducing of PsO cutaneous and joint inflammation and consequently of the CRP levels. The hospital-based and small sample provided by a single referral center, as well as the non-attendance of healthy individuals as control group for comparisons with PsO patients consist in limitations of our study. Additionally, there was no discrimination of subsamples of PsA patients, and the choice method to CRP measurement compared to hs-CRP may result in underestimate analyses of this parameter. However, it attends the study purposes in the fundamental requirements.
CONCLUSIONS
Our study indicated high prevalence of MetS, SAH, obesity and high-intermediate CVR in PsO patients, particularly in women.
We underlined that equivalent and enhancing factors must be considered for CVR global assessment, which would increase the CVR estimative of these patients. CRP is an inflammatory biomarker, also its elevation can establish a close and imbricated relationship between PsO, MetS, SAH, age, HDL-cholesterol and CVR. It is accessible to be adopted in routine and a warning for additional care in the primary prevention and/or decision-making for effective therapy use in cardiovascular disease.
According to our results, the high levels of CRP are shared by PsO and other comorbidities, whose coexistence can establish common consequences and implicate in additional burden for CVR raise. q
